These trials are evaluating the efficacy of the autophagy inhibitor hydroxychloroquine either as a monotherapy or in combination with a checkpoint inhibitor (avelumab), a CDK4/6 inhibitor (palbociclib/ abemaciclib), or an mTOR inhibitor (everolimus) to eliminate dormant cancer cells in BC patients who are in remission but harbour DTCs in their bone marrow. The gene discussed is CDK4; the disease is breast cancer.